Mechanism of Acrolein Toxicity



Kathryn Lund The University of Montana - Western Junior SURP Attendee Summer 2021



Becky Kendall PhD Candidate Andrij Holian Kathryn Lund Director CEHS, Mentor Raymond Hamilton Biostatistician Research was supported by the National Institute Of Environmental Health Sciences of the National Institutes of Health under Award Number R25ES022866. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Effects of Acrolein on Health


 Burning of eyes, skin, nose, throat, etc.

- Routes of exposure:
 - Tobacco smoke
 - Automobile exhaust
 - Inhaling cooking oil and grease
- Common use of acrolein:
 - Biocide and herbicide
 - Production of amino acids




Chemistry of Acrolein

- Simplest unsaturated aldehyde
- Highly reactive
 - Electrophilic carbon
 - Carbonyl group
- Interacts with DNA, proteases, and proteins
 - Transient receptor potential cation channel (TRPA1)
 - Protein tyrosine phosphatase (PTP1B)




PTP1B Involvement with Macrophages




- PTP1B binds to Src kinase to activate cytokine production
- Src kinase activates cytokine production by signaling macrophages
- PTP1B inhibition increases M2 phenotype
- Acrolein alters PTP1B, not allowing it to activate to Src

Aims and Hypothesis




- Show that acrolein inhibits activity of PTP1B in alveolar macrophages in vitro
- Show that acrolein blocks PTP1B activity in lung macrophages in vivo
- Dose response


AM Model



- Alveolar macrophages (AM)- lung immune cell located in the airways and alveoli used for *in vivo* and *in vitro*
 - Bone marrow derived macrophages (BMdM)- generated in lab and stimulated into macrophages for *in vitro* studies



BMdM Model




Researching PTP1B Inhibition *in Vivo*

- BCA assay to determine concentrations of proteins
- Western blot to show:
 - detection of proteins to determine acrolein is getting into the cells *in vivo*
 - reduction of PTP1B due to acrolein *in vivo*




Results of *in Vivo* Exposure



Results of in Vivo Exposure

- Exposed mice to acrolein
 - Treated lavaged AM's with LPS
- Ran ELISA to determine if cytokine signaling pathway was being inhibited
 - TNF alpha
 - IL-6
- Results were inconclusive that acrolein was inhibiting PTP1B or the signaling pathway




Researching Acrolein Exposure in Vitro

- Exposed mouse AM's to acrolein
- Ran MTS assay to determine cell viability
- Treated AM's with LPS
- Ran ELISA to determine if acrolein is inhibiting the cytokine signaling pathway
 - TNF alpha
 - IL-6
- Western blot to determine if Src Kinase is being inhibited




Results of in Vitro Exposure



Conclusion and Future Research

Confirmed AM model is more sensitive to acrolein

- / Dephosphorylated src kinase not dectable in BMdM
- AM model possible dose response in ELISA (TNF & IL-6)
- Confirmed dephosphorylated src kinase disappears in acrolein exposures
- Future research to determine the mechanism of src kinase and acrolein
 - Changes in ratio of phosphorylated to dephosphorylated src kinase
 - NF-kB activity
 - Improved dose response in vitro and in vivo



Acknowledgements

Thank you!

- Ray Hamilton
- Andrij Holian
- Chris Migliaccio
- Mary Buford
- Becky Kendall
- Brit Postma



Funding: R25 ES022866 from the National Institute for Environmental Health Sciences

References

Agency for Toxic Substances and Disease Registry (ATSDR). 2007. <u>Toxicological Profile for Acrolein (Update</u>). Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service.

Nassini R, Materazzi S, Benemei S, Geppetti P. The TRPA1 channel in inflammatory and neuropathic pain and migraine. Rev Physiol Biochem Pharmacol. 2014;167:1-43. doi: 10.1007/112_2014_18. PMID: 24668446.